MedTrace Logo

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

NCT04479631 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-03-03

No results posted yet for this study

Summary

This is a phase 1 study in which healthy adult volunteers will receive BRII-196 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

Conditions

Interventions

DRUG

BRII-196

BRII-196 given intravenously

DRUG

Placebo

Placebo given intravenously

Sponsors & Collaborators

  • TSB Therapeutics (Beijing) CO.LTD

    collaborator INDUSTRY

  • Brii Biosciences Limited

    lead INDUSTRY

Principal Investigators

  • Yao Zhang · TSB Therapeutics (Beijing) CO.LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-12
Primary Completion
2021-01-29
Completion
2021-01-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04479631 on ClinicalTrials.gov